Literature DB >> 23139022

Identification of small molecules that interfere with H1N1 influenza A viral replication.

Angel Bottini1, Surya K De, Bas J G Baaten, Bainan Wu, Elisa Barile, Stephen Soonthornvacharin, John L Stebbins, Linda M Bradley, Sumit K Chanda, Maurizio Pellecchia.   

Abstract

Successful replication of the influenza A virus requires both viral proteins and host cellular factors. In this study we used a cellular assay to screen for small molecules capable of interfering with any of such necessary viral or cellular components. We used an established reporter assay to assess influenza viral replication by monitoring the activity of co-expressed luciferase. We screened a diverse chemical compound library, resulting in the identification of compound 7, which inhibits a novel yet elusive target. Quantitative real-time PCR studies confirmed the dose-dependent inhibitory activity of compound 7 in a viral replication assay. Furthermore, we showed that compound 7 is effective in rescuing high-dose influenza infection in an in vivo mouse model. As oseltamivir-resistant influenza strains emerge, compound 7 could be further investigated as a new and potentially suitable scaffold for the development of anti-influenza agents that act on novel targets.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23139022      PMCID: PMC3769975          DOI: 10.1002/cmdc.201200453

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  12 in total

Review 1.  Endocytosis of influenza viruses.

Authors:  Melike Lakadamyali; Michael J Rust; Xiaowei Zhuang
Journal:  Microbes Infect       Date:  2004-08       Impact factor: 2.700

2.  The significance of p53 and retinoblastoma pathways in canine hemangiosarcoma.

Authors:  Kayoko Yonemaru; Hiroki Sakai; Mami Murakami; Atsushi Kodama; Takashi Mori; Tokuma Yanai; Kohji Maruo; Toshiaki Masegi
Journal:  J Vet Med Sci       Date:  2007-03       Impact factor: 1.267

3.  Evidence that the amantadine-induced, M2-mediated conversion of influenza A virus hemagglutinin to the low pH conformation occurs in an acidic trans Golgi compartment.

Authors:  F Ciampor; P M Bayley; M V Nermut; E M Hirst; R J Sugrue; A J Hay
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

4.  BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.

Authors:  Supriya Gaitonde; Surya K De; Marianna Tcherpakov; Antimone Dewing; Hongbin Yuan; Megan Riel-Mehan; Stan Krajewski; Gavin Robertson; Maurizio Pellecchia; Ze'ev Ronai
Journal:  Pigment Cell Melanoma Res       Date:  2009-01-17       Impact factor: 4.693

5.  CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.

Authors:  Makoto Yamashita; Takanori Tomozawa; Masayo Kakuta; Akane Tokumitsu; Hatsumi Nasu; Shuku Kubo
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

6.  Human host factors required for influenza virus replication.

Authors:  Renate König; Silke Stertz; Yingyao Zhou; Atsushi Inoue; H-Heinrich Hoffmann; Suchita Bhattacharyya; Judith G Alamares; Donna M Tscherne; Mila B Ortigoza; Yuhong Liang; Qinshan Gao; Shane E Andrews; Sourav Bandyopadhyay; Paul De Jesus; Buu P Tu; Lars Pache; Crystal Shih; Anthony Orth; Ghislain Bonamy; Loren Miraglia; Trey Ideker; Adolfo García-Sastre; John A T Young; Peter Palese; Megan L Shaw; Sumit K Chanda
Journal:  Nature       Date:  2010-02-11       Impact factor: 49.962

7.  Structure and mechanism of the M2 proton channel of influenza A virus.

Authors:  Jason R Schnell; James J Chou
Journal:  Nature       Date:  2008-01-31       Impact factor: 49.962

Review 8.  Emerging antiviral targets for influenza A virus.

Authors:  Robert M Krug; James M Aramini
Journal:  Trends Pharmacol Sci       Date:  2009-05-08       Impact factor: 14.819

9.  Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.

Authors:  J McKimm-Breschkin; T Trivedi; A Hampson; A Hay; A Klimov; M Tashiro; F Hayden; M Zambon
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  Matrix metalloprotease 9 mediates neutrophil migration into the airways in response to influenza virus-induced toll-like receptor signaling.

Authors:  Linda M Bradley; Mia F Douglass; Dhrubamitra Chatterjee; Shizuo Akira; Bas J G Baaten
Journal:  PLoS Pathog       Date:  2012-04-05       Impact factor: 6.823

View more
  6 in total

1.  Targeting Influenza A Virus RNA Promoter.

Authors:  Angel Bottini; Surya K De; Bainan Wu; Changyan Tang; Gabriele Varani; Maurizio Pellecchia
Journal:  Chem Biol Drug Des       Date:  2015-03-13       Impact factor: 2.817

Review 2.  Development and applications of single-cycle infectious influenza A virus (sciIAV).

Authors:  Aitor Nogales; Steven F Baker; William Domm; Luis Martínez-Sobrido
Journal:  Virus Res       Date:  2015-07-26       Impact factor: 3.303

Review 3.  New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions.

Authors:  Grant Beyleveld; Kris M White; Juan Ayllon; Megan L Shaw
Journal:  Antiviral Res       Date:  2013-08-06       Impact factor: 5.970

Review 4.  Novel Approaches for The Development of Live Attenuated Influenza Vaccines.

Authors:  Pilar Blanco-Lobo; Aitor Nogales; Laura Rodríguez; Luis Martínez-Sobrido
Journal:  Viruses       Date:  2019-02-22       Impact factor: 5.048

5.  Identification of Quinolinones as Antivirals against Venezuelan Equine Encephalitis Virus.

Authors:  Nicole N Haese; Nicholas A May; Sharon Taft-Benz; Omar Moukha-Chafiq; Nikhil Madadi; Sixue Zhang; Shuklendu D Karyakarte; Kevin J Rodzinak; Theresa H Nguyen; Michael Denton; Aaron D Streblow; Nichole A Towers; Lynn Rasmussen; Robert J Bostwick; Joseph A Maddry; Subramaniam Ananthan; Corinne E Augelli-Szafran; Mark J Suto; Wes Sanders; Nathaniel Moorman; Victor DeFilippis; Mark T Heise; Ashish K Pathak; Daniel N Streblow; Thomas E Morrison
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

6.  miR-29a is a negative regulator of influenza virus infection through targeting of the frizzled 5 receptor.

Authors:  Xiaoyun Yang; Yurong Liang; Gayan Bamunuarachchi; Yanzhao Xu; Kishore Vaddadi; Samuel Pushparaj; Dao Xu; Zhengyu Zhu; Rachel Blaha; Chaoqun Huang; Lin Liu
Journal:  Arch Virol       Date:  2020-11-18       Impact factor: 2.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.